Kalra, Philip A.
Bhandari, Sunil
Spyridon, Michael
Davison, Rachel
Lawman, Sarah
Mikhail, Ashraf
Reaich, David
Pritchard, Nick
McCafferty, Kieran
Moore, Jason
Funding for this research was provided by:
Pharmacosmos UK Ltd
Article History
Received: 12 March 2020
Accepted: 19 November 2020
First Online: 10 December 2020
Ethics approval and consent to participate
: The Health Research Authority and the Regional Ethics Committee in the UK (reference: 15/EM/0303) approved the study and all subsequent protocol amendments. All study participants gave written informed consent before inclusion into the study, and the study was performed in accordance with Good Pharmacovigilance Practices and the European Medicines Agency criteria for non-interventional studies [CitationRef removed].
: Not applicable.
: Pharmacosmos UK Ltd. sponsored the study. PAK and SB have received consultancy fees, speaker honoraria and educational grants from Pharmacosmos and Vifor Pharma. MS is an employee of Pharmacosmos UK Ltd. RD has received consultancy fees, speaker honoraria and educational grants from Pharmacosmos. DR has received consultancy fees and educational grants from Pharmacosmos. SL has received consultancy fees from Pharmacosmos. AM and KM have received consultancy fees from Pharmacosmos and Vifor Pharma. NP has received speaker honoraria from Pharmacosmos. JM has no conflicts of interest.